Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

This study is testing targeted therapy drugs given before surgery (called neoadjuvant therapy) in people with a specific type of lung cancer — squamous cell carcinoma with an EGFR gene mutation — to try to shrink the tumor before it is removed. **You may be eligible if...** - You are 18 or older - You have stage II–IIIB lung squamous cell carcinoma that can be surgically removed - Your tumor has an EGFR gene mutation confirmed by genetic testing - Scans confirm the cancer has not spread to other parts of the body - You are in generally good health **You may NOT be eligible if...** - You have had another cancer in the past 5 years - You have uncontrolled infections, heart failure, autoimmune disease, or active bleeding - You have HIV or active hepatitis - You have had major surgery in the last 2 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.